Table 1 Demographics and baseline characteristics
Characteristics | Montelukast monotherapy | Montelukast + ICS | Total | ||||
|---|---|---|---|---|---|---|---|
Preschool age | School age | All | Preschool age | School age | All | ||
N | 34 | 42 | 76 | 112 | 140 | 252 | 328 |
Age (years), mean (SD) | 4.01 (1.12) | 9.19 (2.26) | 6.87 (3.19) | 3.86 (1.13) | 9.54 (2.35) | 7.02 (3.41) | 6.92 (3.35) |
Gender, n (%) | |||||||
Male | 18 (52.9) | 25 (59.5) | 43 (56.6) | 60 (53.6) | 89 (63.6) | 149 (59.1) | 192 (58.5) |
Female | 16 (47.1) | 17 (40.5) | 33 (43.4) | 52 (46.4) | 51 (36.4) | 103 (40.9) | 136 (41.5) |
Race, n (%) | |||||||
Caucasian | 25 (73.5) | 32 (76.2) | 57 (75.0) | 66 (58.9) | 86 (61.4) | 152 (60.3) | 209 (63.7) |
Black | 0 (0.0) | 1 (2.4) | 1 (1.3) | 8 (7.1) | 13 (9.3) | 21 (8.3) | 22 (6.7) |
Asian | 4 (11.8) | 8 (19.0) | 12 (15.8) | 32 (28.6) | 32 (22.9) | 64 (25.4) | 76 (23.2) |
Hispanic | 0 (0.0) | 1 (2.4) | 1 (1.3) | 3 (2.7) | 3 (2.1) | 6 (2.4) | 7 (2.1) |
Other | 3 (8.8) | 0 (0.0) | 3 (3.9) | 2 (1.8) | 6 (4.3) | 8 (3.2) | 11 (3.4) |
Missing | 2 (5.9) | 0 (0.0) | 2 (2.6) | 1 (0.9) | 0 (0.0) | 1 (0.4) | 3 (0.9) |
Duration of asthma since diagnosis (years), mean (SD) | 2.06 (1.11) | 4.32 (3.25) | 3.31 (2.76) | 2.11 (1.27) | 5.46 (3.08) | 3.97 (2.96) | 3.82 (2.92) |
Smoking history, n (%) | |||||||
Patient is a smoker | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Patient quit smoking | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.7) | 1 (0.4) | 1 (0.3) |
Patient never smoked | 34 (100.0) | 41 (97.6) | 75 (98.7) | 104 (92.9) | 133 (95.0) | 237 (94.0) | 312 (95.1) |
Member of household is a smoker | 8 (23.5) | 14 (33.3) | 22 (28.9) | 20 (17.9) | 40 (28.6) | 60 (23.8) | 82 (25.0) |
Member of household quit smoking | 5 (14.7) | 11 (26.2) | 16 (21.1) | 8 (7.1) | 7 (5.0) | 15 (6.0) | 31 (9.5) |
Use of ICS at baseline, n (%) | |||||||
Low dose* | - | - | - | 58 (51.8) | 39 (27.9) | 97 (38.5) | 97 (29.6) |
Moderate dose† | - | - | - | 53 (47.3) | 90 (64.3) | 143 (56.7) | 143 (43.6) |
High dose‡ | - | - | - | 1 (0.9) | 11 (7.9) | 12 (4.8) | 12 (3.7) |
Profile of asthma symptoms, n (%) | |||||||
1. Daytime symptoms ≥ 4 days/week | 24 (70.6) | 26 (61.9) | 50 (65.8) | 91 (81.3) | 106 (75.7) | 197 (78.2) | 247 (75.3) |
2. Night-time symptoms ≥ 1 night/week | 29 (85.3) | 30 (71.4) | 59 (77.6) | 99 (88.4) | 111 (79.3) | 210 (83.3) | 269 (82.0) |
3. Absenteeism from school due to asthma in the last week | 7 (20.6) | 16 (38.1) | 23 (30.3) | 33 (29.5) | 66 (47.1) | 99 (39.3) | 122 (37.2) |
4. SABA ≥ 4 doses in the last week§ | 13 (38.2) | 13 (31.0) | 26 (34.2) | 76 (67.9) | 92 (65.7) | 168 (66.7) | 194 (59.1) |
5. FEV in one second or PEF ≥90% of their personal best in the last week | 2 (5.9) | 9 (21.4) | 11 (14.5) | 11 (9.8) | 41 (29.3) | 52 (20.6) | 63 (19.2) |
6. Diurnal variability in peak expiratory flow >10% to 15% in the last week | 2 (5.9) | 2 (4.8) | 4 (5.3) | 8 (7.1) | 22 (15.7) | 30 (11.9) | 34 (10.4) |